Central IRBs: Ceding IRB Oversight

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

All you always wanted to know about Assurances Office of Research Protections (ORP) U.S. Army Medical Research and Materiel Command (USAMRMC) Fort Detrick,
THE UW HEALTH SCIENCES IRB S OVERVIEW PRACTICAL REGULATORY ISSUES IN HUMAN SUBJECTS RESEARCH.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
Multisite Human Subjects Research CUNY HRPP Coordinator Training October 19, 2012.
ANPRM Single IRB Review mandated for multi-site domestic research P. Pearl O’Rourke, M.D. Partners Health Care.
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
John Naim, PhD Director Clinical Trials Research Unit
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
CUMC IRB Investigator Meeting IRB Frequently Asked Questions October 11, 2005.
October 19, 2010 Steven Hirschfeld, MD, PhD Julia Slutsman, PhD
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
HRPP Policies & Forms Created/Revised for AAHRPP.
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Institutional Review Board (IRB) Human Subject Research Office (HSRO) University of Miami and Affiliated Institutions.
IRBMED AND CHESAPEAKE IRB General Procedures for Ceding IRBMED Oversight Procedures Specific to Chesapeake IRB Medical School Institutional Review Board.
Federalwide Assurance Presentation for IRB Members.
International Research & Research Involving Children K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development.
Chesapeake Research Review, Inc. Human Research Protection Experts IRB Services Consultation Education 1 Holding External IRBs Accountable: An Independent.
Taking the Plunge: Facilitating and Monitoring Collaborative Research and IRB Authorization Agreements Charles Hite Director, Biomedical & Research Ethics.
Using Technology to Strengthen Human Subject Protections Patricia Scannell Director, IRB Washington University School of Medicine.
Help us Help you: IRB Policy Updates Susan Bankowski, MS, JD IRB Chair.
Secretary’s Advisory Committee on Human Subjects Protections (SACHRP) Summary of Responses on: Advanced Notice of Proposed Rulemaking (ANPRM) on Holding.
The Institutional Review Board: A Community College Toolkit Dr. Geri J Anderson.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Yadvindera (Bobby) Bains MD Director of Radiation Oncology, Laredo Medical Center Adjunct Associate Professor, Dept of Radiation Oncology, University of.
Central IRBs: More Efficient for Whom? May 7, 2012 P. Pearl O’Rourke, M.D. Partners HealthCare Boston, MA.
SACHRP PANEL: HOLDING EXTERNAL IRBS ACCOUNTABLE David L. Wynes, Ph.D. Vice President for Research Administration Emory University July 21, 2009.
Investigational Devices and Humanitarian Use Devices June 2007.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
Updates in Research Protections Karen Allen Director, Research Protections Office of Research November
 Welcome ◦ Amanda Athey, Director, Graduate School  Student Experience  Funding Opportunities ◦ Rebecca Drake, Research Administrator, Office of Research.
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
Emerging SACHRP Issues K. Lynn Cates, MD Assistant Chief Research & Development Officer Director, PRIDE Office of Research & Development Department of.
VA Central IRB K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development Department of Veterans Affairs.
VA Central IRB K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development Department of Veterans Affairs September.
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Using A Central IRB At Thomas Jefferson University / Hospital Roseann Talarico Associate Director Office of Human Research.
Multi-site Research - Central/Single IRBs - Data sharing questions P. Pearl O’Rourke, MD Partners HealthCare October 26, 2015.
Submitting to a Commercial IRB Kyle Conner, MA, CIP Associate Director Office of Human Research.
IRB Open House: Implementation of Single IRB Review
Overview: IRBshare  IRBchoice
Ceding Review: Using the new SmartIRB Online Reliance System
Reportable Events & Other IRB Updates February 2017
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Multisite Human Subjects Research
UW-Madison Central IRB Gateway
Michael Linke, PhD, CIP Professor Department of Internal Medicine
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
HHS Reporting Requirements and Adverse Events
Changes to the Common Rule and Single IRB (sIRB)
IRB Harmonization 2016 Review
Event Reporting in Human Subjects Research
Quality Assurance in Clinical Trials
CTSA27 So you want COMIRB to be your sIRB: What you need to know.
Hannah Helmstetter & Meredith Capasse July 12, 2019
Common Rule
Sleep SMART Clinical Trial Agreements / Regulatory Webinar
Michael Linke, PhD, CIP Professor Department of Internal Medicine
Research with Human Subjects
Dr. Julie Doherty, DM, MSN,RN, CIP, CCEP
Presentation transcript:

Central IRBs: Ceding IRB Oversight Judy Birk, JD IRBMED Director

Presentation Outline Defining and explaining a Central IRB IRBMED ceding oversight Focus on commercial IRBs IRBMED accepting oversight Brief information Brief FAQs

What is a Central IRB? A single IRB Provides regulatory and ethical oversight for research conducted by one or more institutions not otherwise affiliated with it Per specific agreement, it becomes the IRB of Record for oversight of the research at all sites

Establishing the Relationship Federal regulations allow FWA-holding IRBs to enter into joint review agreements to reduce regulatory burden Central IRBs may be Independent (commercial) Academic Agreements may also be called Reliance Agreements Cooperative Agreement IRB of Record Agreements Master Service Agreements IRB Authorization Agreements (IAA) – OHRP terminology

Common Scenarios for Use of Central IRBs Multi-site studies Industry-sponsored Federally-sponsored Time-sensitive studies Public health emergency such as flu Specialized IRB expertise is necessary Special populations Specialized reviewers

Potential Benefits Eliminates full, duplicative review across sites Reduces variability of the study parameters across sites Decreases cumulative review time Decreases burdens on local IRBs Costs are reduced locally and perhaps for the study as a whole

Perceived Challenges Quality and thoroughness of review How well do you know the central IRB? Consideration of local context How well does the central IRB know you? Apportionment of institutional liability How will problems be managed? Managing ‘shared’ control and accountability Who will perform certain functions? Agreeing to different standardized procedures New workflows may be necessary

Misperceptions Ceding oversight lets PIs avoid IRBMED, ORSP, CRAO, COI, and other ancillary committees WRONG! Only IRBMED oversight is ceded. The regulatory oversight will be different with another IRB WRONG! All IRBs follow the same regulatory authority. All Central IRBs have the same process WRONG! Each IRB has their own process for applying.

Ceding to a Central IRB Collaborating institutions complete the agreement document Roles and responsibilities are apportioned FWAs are amended, if necessary (OHRP) Assure all internal institutional documents are in alignment with the arrangements Informed consent template language is finalized Does not require OHRP or FDA signature or approval

IRBMED Ceding Parameters for Central (Commercial) IRBs All requests are evaluated on a case-by-case basis. Parameters: Multi-site Industry-sponsored Federally-sponsored (rare) Phase II, III, and IV U-M must not be a coordinating center NCI-CIRB clinical trials (all phases)

Finalized IRBMED Agreements - Ceding Ceding oversight Single academic institutions Independent (central/commercial IRBs) Schulman Associates IRB Western IRB (WIRB)/Copernicus IRB Chesapeake IRB Quorum Review IRB NCI CIRB Generally, an IRB must be accredited or well-known to U-M before IRBMED will cede IRB oversight

Who May Request to Cede Oversight? Sponsor CRO External Institution / Individual Grant/award U-M PI

Application Process Study teams create a Clinical Trial Routing Form (CTRF) in eResearch Proposal Management (eRPM) Select the Central IRB (check with IRBMED if the IRB is not listed) In eResearch Regulatory Management (eRRM), complete the “Requesting Review by a Non-UM IRB” (“Ceding”) application. The Ceding application is routed to/reviewed by the ancillary committees The Ceding application is reviewed and acknowledged by IRBMED

Ongoing PI/Study Team Obligations at U-M Amendments must be submitted for any Changes to the U-M study team membership Changes to the research impacting ancillary committee reviews COI CRAO Investigational Pharmacy RDRC/SHUR Changes to research may impact IRBMED’s decision to cede the project to the central IRB Noncompliance of the Central IRB

Ongoing PI/Study Team Obligations at U-M AE/ORIO reports must be submitted if: Related, serious adverse events occur in U-M subjects Unanticipated problems occur in U-M subjects Serious and/or continuing non-compliance determinations are made regarding U-M participation The study is placed on hold or suspended

Ongoing PI/Study Team Obligations at U-M Continuing reviews or termination reports The research study continues to be approved at the Central IRB The research study is terminated at the Central IRB

IRBMED Agreements-Accepting Accepting oversight Single academic institutions Single non-academic sites (e.g., private medical practice) Single individuals (e.g., a consultant on a study) Generally, the studies/roles of the individual at the external institution are of lower risk

IRBMED is Accepting Oversight *PI/Study Team Actions Contact IRBMED Application to Request IRBMED Oversight Provides details about the roles/responsibilities and the relationship Identify the collaborators in eResearch Complete any additional documentation requested by IRBMED Work with IRBMED to obtain/provide any additional documentation to/from the external site/individual

IRBMED is Accepting Oversight *IRBMED Actions Collect documentation from PI/Study team Review ‘Application Requesting IRBMED Oversight’ Consult with IRBMED Directors and UMOR (formerly OVPR) Pre-screening to resolve outstanding questions Seek approval from IRBMED co-Chairs and other designated officials UMOR reviews the request and signs the agreement External institution signs Agreement is uploaded into eResearch

IRBMED as a Central IRB? IRBMED as a Central IRB for multi-site research is under consideration

FAQs for Ceding to a Central IRB Q: How long does the application review process take at IRBMED? A: If all agreements are in place, review of the ceding application received by IRBMED should take approximately 2 business days. Q: Do I use the IRBMED consent or the sponsor’s consent? A: Generally, you will use the sponsor’s consent that includes U-M required language.

FAQs for Ceding to a Central IRB Q: Who pays for the cost of a Central (commercial) IRB? A: Usually, the sponsor does. Q: I am a U-M sponsor-investigator of a research study – may I use a Central (commercial) IRB? A: No, not at this time.

Resources NIAID Research Toolkit OHRP Website IRBMED Website for Central IRBs

Questions? Thank you!